Centre of Pediatric Hematology Oncology Immunology named after D. Rogachev

04/09/2019

Deep learning enables rapid identification of potent DDR1 kinase inhibitors

A machine learning model allows the identification of new small-molecule kinase inhibitors in days.

08/12/2016

#2 most popular paper in Aging by FNKC scientists:
http://www.aging-us.com/article/SzdNR3HCatAdyvwPR/text

19/12/2014

Поздравляем Алексея Москалева, а также ученых ФНКЦ ДГОИ с публикацией статьи о эффектах стресс факторов в известном научном журнале.

Ionizing radiation in low doses is the ubiquitous environmental factor with harmful stochastic effects. Formaldehyde is one of the most reactive household and industrial pollutants. Dioxins are persistent organic pollutants and most potent synthetic poisons effective even at trace concentrations. En…

11/11/2013

On 8 November a delegation from the Netherlands paid a visit to the FSCC PHOI n.a. D. Rogachev. Minister of Health, Welfare and Sport of the Netherlands Edith Schippers was in the delegation.

07/11/2013

Hans D. Ochs, MD, is attending physician at Seattle Children’s Hospital; and co-director of the Immunology Diagnostic Laboratory at Seattle Children’s Research Institute. He earned his MD summa cm laude from the University of Freiburg, Germany. He completed his residency in pediatrics at the University of Washington.

30/10/2013

#миссвселенная

The contestants

30/10/2013

Miss Universe 2013 will be the 62nd Miss Universe pageant. It will be held on November 9, 2013 at the Crocus City Hall in Moscow, Russia. Olivia Culpo, Miss Universe 2012 from the USA will crown her successor at the end of the event. Eighty-six countries and territories will participate in the event. #миссвселенная

23/10/2013

Prospective data collection in modern paediatric radiation oncology for radiation doses, acute and late effects.

16/10/2013

15/10/2013

https://www.facebook.com/media/set/?set=a.454223041366060.1073741860.314849281970104&type=3

Donald Small in Center for Pediatric Hematology, Oncology and Immunology

15/10/2013

Donald Small, M.D., Ph.D.
Biography:
Dr. Small received his undergraduate, and then M.D. and Ph.D. degrees from the Johns Hopkins University in 1979 and 1985. His Ph.D. research was conducted with Bert Vogelstein in the Oncology Department and his postdoctoral research with Tom Kelly in the Molecular Biology and Genetics Department. He trained in pediatrics and pediatric hematology/oncology at Johns Hopkins and joined the faculty in 1990 where he moved up the ranks and is the Kyle Haydock Professor of Oncology with joint appointments in Pediatrics and Cellular and Molecular Medicine and Human Genetics. He has been the Director of Pediatric Oncology since 2006.

His laboratory was the first to clone the human FLT3 gene that is the most frequently mutated gene in acute myeloid leukemia (AML) and results in very poor chances of cure for these patients. They investigated its role in leukemia and were the first to discover drugs able to inhibit the tyrosine kinase activity of FLT3. His laboratory showed that this class of drugs would preferentially kill leukemic cell lines and primary AML samples expressing mutant FLT3. Thus, this is one of the first examples of molecularly targeted therapy for cancer. They developed a high-throughput cell-based in vitro assay that enabled them to screen a large library of kinase inhibitors and find several with great potency and selectivity against FLT3. His group led the first clinical trials investigating the use of a FLT3 inhibitor in adult relapsed and refractory FLT3 mutant AML, and determined how to best combine these drugs with chemotherapy. They also helped design the first pediatric trials of FLT3 inhibitors in pediatric AML and infant ALL.

His lab continues to study the process of leukemic transformation and the role of FLT3 in leukemia stem cells through the generation of mouse models and by studying signaling changes in these cells.

15/10/2013

Donald Small in Center for Pediatric Hematology, Oncology and Immunology